ArticleAmerican journal of cancer research2021
ImmunoPET of the differential expression of CD146 in breast cancer.
Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Enhanced Tumor-to-Background Contrast with [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Looking backward to move forward: a chemist's perspective on the future of radiopharmaceuticals.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Article
- Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives.Clinical and translational science · 2025Article
- HER2 expression in different cell lines at different inoculation sites assessed by [Pathology oncology research : POR · 2025Article
- Antigen targeting and anti-tumor activity of a novel anti-CD146Scientific reports · 2024Article
- Development ofMolecular imaging and biology · 2024Article
- CD146-targeted nuclear medicine imaging in cancer: state of the art.View (Beijing, China) · 2023Article
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advancement in antibody engineering, the development and characterization of new cancer-specific molecular targets are in the forefront of this PET-antibody combination "revolution". Overexpression of CD146 in different types of tumors, including breast tumor, has been associated with tumor progression and poor prognosis. Non-invasive detection of CD146 with a monoclonal antibody may provide a noninvasive diagnostic tool with high specificity and accountability.
methodsHerein, we have developed a CD146-specific monoclonal antibody (YY146), radiolabeled it with
resultsWestern Blot results show that MDA-MB-435 cell line had greater levels of CD146 expression when compared to the other cell lines investigated. Flow cytometry confirmed binding ability of YY146. PET images revealed well correlated uptake between tumor uptake and CD146 expression levels, confirmed by biodistribution studies and fluorescence imaging.
conclusionPET imaging, for up to 7 days, of mice bearing three different breast tumors were carried out and revealed radiotracer uptake in tumors that strongly (r
Indexed as
Identifiers
33948375PMC8085863W3158266544What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.